AP611074 5% gel + AP611074 matching placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Condyloma
Conditions
Condyloma
Trial Timeline
Jan 1, 2016 → Jul 1, 2018
NCT ID
NCT02724254About AP611074 5% gel + AP611074 matching placebo
AP611074 5% gel + AP611074 matching placebo is a phase 2 stage product being developed by Vaxart for Condyloma. The current trial status is completed. This product is registered under clinical trial identifier NCT02724254. Target conditions include Condyloma.
What happened to similar drugs?
0 of 1 similar drugs in Condyloma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02724254 | Phase 2 | Completed |
Competing Products
2 competing products in Condyloma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine + Comparator: placebo (unspecified) | Merck | Phase 3 | 40 |
| Leukocyte Interleukin, Injection 200IU + Leukocyte Interleukin, injection 400IU | CEL-SCI | Phase 1 | 11 |